In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
José María SayaguésDepartment of Pathology, Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, 37007 Salamanca, Spain.ORCID 0000-0003-0582-3500 Mar AbadDepartment of Pathology, Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, 37007 Salamanca, Spain.
Diego Bueno-SacristánDepartment of Pathology, Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, 37007 Salamanca, Spain.ORCID 0000-0003-4785-5711 Magdalena SanchoDepartment of Pathology, Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, 37007 Salamanca, Spain.
María Belen RivasDepartment of Pathology, Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, 37007 Salamanca, Spain.
María Teresa Alonso-MárquezDepartment of Pathology, Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, 37007 Salamanca, Spain.
Ana María MorenoDepartment of Pharmacy, Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, 37007 Salamanca, Spain.
Juan Carlos MonteroDepartment of Pathology, Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, 37007 Salamanca, Spain.ORCID 0000-0003-4773-053X Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Pancreatic ductal adenocarcinoma (PDAC) is molecularly characterized by near-universal
Indexed as
Carcinoma, Pancreatic DuctalEukaryotic Initiation FactorsOncogene Proteins, FusionPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)ThrombospondinsFemaleHumansMiddle AgedR-SpondinsEukaryotic Initiation FactorsKRAS protein, humanOncogene Proteins, FusionProto-Oncogene Proteins p21(ras)R-SpondinsThrombospondinsEIF3E::RSPO2gene fusionPDACpersonalized medicinetumor genomicsWnt/β-catenin pathway
Identifiers
PMID42449953
PMCPMC13362383
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390